TherapeuticsMD, Inc.
US ˙ NasdaqGS ˙ US88338N2062

Introduction

This page provides a comprehensive analysis of the known insider trading history of Michael C Donegan. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Michael C Donegan has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:TXMD / TherapeuticsMD, Inc. Prin. Fin. and Acctg. Officer 61,853
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Michael C Donegan. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases TXMD / TherapeuticsMD, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in TXMD / TherapeuticsMD, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TXMD / TherapeuticsMD, Inc. Insider Trades
Insider Sales TXMD / TherapeuticsMD, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in TXMD / TherapeuticsMD, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2023-01-27 TXMD Donegan Michael C 49 5.0900 49 5.0900 249 272 2.0000 -151 -60.64
2023-01-26 TXMD Donegan Michael C 1,648 5.0796 1,648 5.0796 8,371
2023-01-24 TXMD Donegan Michael C 7 5.3101 7 5.3101 37
2023-01-23 TXMD Donegan Michael C 1,302 5.3383 1,302 5.3383 6,950
2022-12-06 TXMD Donegan Michael C 910 4.7750 910 4.7750 4,345
2021-11-30 TXMD Donegan Michael C 29,790 0.5353 596 26.7650 15,947
2021-05-11 TXMD Donegan Michael C 4,842 1.0400 97 52.0000 5,036

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TXMD / TherapeuticsMD, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Michael C Donegan as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2023-04-14 2023-04-12 4 TXMD TherapeuticsMD, Inc.
Common Stock
M - Exercise 50,000 61,853 421.83
2023-01-30 2023-01-27 4 TXMD TherapeuticsMD, Inc.
Common Stock
S - Sale -49 11,853 -0.41 5.09 -249 60,332
2023-01-30 2023-01-26 4 TXMD TherapeuticsMD, Inc.
Common Stock
S - Sale -1,648 11,902 -12.16 5.08 -8,371 60,457
2023-01-30 2023-01-26 4 TXMD TherapeuticsMD, Inc.
Common Stock
M - Exercise 1,140 13,550 9.19
2023-01-30 2023-01-26 4 TXMD TherapeuticsMD, Inc.
Common Stock
M - Exercise 2,400 12,410 23.98
2023-01-30 2023-01-26 4 TXMD TherapeuticsMD, Inc.
Common Stock
M - Exercise 2,400 12,410 23.98
2023-01-25 2023-01-24 4 TXMD TherapeuticsMD, Inc.
Common Stock
S - Sale -7 7,610 -0.09 5.31 -37 40,410
2023-01-25 2023-01-23 4 TXMD TherapeuticsMD, Inc.
Common Stock
S - Sale -1,302 7,617 -14.60 5.34 -6,950 40,662
2023-01-25 2023-01-23 4 TXMD TherapeuticsMD, Inc.
Common Stock
M - Exercise 2,400 8,919 36.82
2023-01-25 2023-01-23 4 TXMD TherapeuticsMD, Inc.
Common Stock
M - Exercise 519 6,519 8.65
2023-01-25 2023-01-23 4 TXMD TherapeuticsMD, Inc.
Common Stock
M - Exercise 1,066 6,000 21.61
2023-01-25 2023-01-23 4 TXMD TherapeuticsMD, Inc.
Common Stock
M - Exercise 380 4,934 8.34
2022-12-09 2022-12-06 4 TXMD TherapeuticsMD, Inc.
Common Stock
S - Sale -910 4,554 -16.65 4.78 -4,345 21,745
2022-12-09 2022-12-06 4 TXMD TherapeuticsMD, Inc.
Common Stock
M - Exercise 262 5,464 5.04
2022-12-09 2022-12-06 4 TXMD TherapeuticsMD, Inc.
Common Stock
M - Exercise 534 5,202 11.44
2022-12-09 2022-12-06 4 TXMD TherapeuticsMD, Inc.
Common Stock
M - Exercise 380 4,668 8.86
2022-12-09 2022-12-06 4 TXMD TherapeuticsMD, Inc.
Common Stock
M - Exercise 2,300 4,288 115.69
2022-03-31 2022-03-31 4 TXMD TherapeuticsMD, Inc.
Performance Stock Units
A - Award 120,000 120,000
2022-03-28 2022-03-23 4 TXMD TherapeuticsMD, Inc.
Restricted Stock Units
A - Award 120,000 120,000
2021-12-02 2021-11-30 4 TXMD TherapeuticsMD, Inc.
Restricted Stock Units
M - Exercise -115,000 115,000 -50.00
2021-12-02 2021-11-30 4 TXMD TherapeuticsMD, Inc.
Common Stock
S - Sale -29,790 99,368 -23.06 0.54 -15,947 53,192
2021-12-02 2021-11-30 4 TXMD TherapeuticsMD, Inc.
Common Stock
M - Exercise 115,000 129,158 812.26
2021-10-01 2021-09-29 4 TXMD TherapeuticsMD, Inc.
Non-Qualified Stock Option (right to buy)
J - Other -100,000 0 -100.00
2021-10-01 2021-09-29 4 TXMD TherapeuticsMD, Inc.
Non-Qualified Stock Option (right to buy)
J - Other -100,000 0 -100.00
2021-10-01 2021-09-29 4 TXMD TherapeuticsMD, Inc.
Non-Qualified Stock Option (right to buy)
J - Other -40,000 0 -100.00
2021-10-01 2021-09-29 4 TXMD TherapeuticsMD, Inc.
Non-Qualified Stock Option (right to buy)
J - Other -50,000 0 -100.00
2021-10-01 2021-09-29 4 TXMD TherapeuticsMD, Inc.
Restricted Stock Units
A - Award 38,954 38,954
2021-07-02 2021-07-01 4 TXMD TherapeuticsMD, Inc.
Restricted Stock Units
A - Award 80,000 80,000
2021-07-02 2021-07-01 4 TXMD TherapeuticsMD, Inc.
Performance Stock Units
A - Award 160,000 160,000
2021-05-12 2021-05-11 4 TXMD TherapeuticsMD, Inc.
Common Stock
S - Sale -4,842 14,158 -25.48 1.04 -5,036 14,724
2021-05-12 2021-05-10 4 TXMD TherapeuticsMD, Inc.
Restricted Stock Units
M - Exercise -19,000 38,000 -33.33
2021-05-12 2021-05-10 4 TXMD TherapeuticsMD, Inc.
Common Stock
M - Exercise 19,000 19,000
2020-11-27 2020-11-24 4 TXMD TherapeuticsMD, Inc.
Restricted Stock Units
A - Award 230,000 230,000
2020-04-01 2020-03-30 4 TXMD TherapeuticsMD, Inc.
Performance Stock Units
A - Award 57,000 57,000
2020-04-01 2020-03-30 4 TXMD TherapeuticsMD, Inc.
Restricted Stock Units
A - Award 57,000 57,000
2019-08-30 2019-08-28 4 TXMD TherapeuticsMD, Inc.
Non-Qualified Stock Option (right to buy)
A - Award 120,000 120,000
2018-03-19 2018-03-15 4 TXMD TherapeuticsMD, Inc.
Non-Qualified Stock Option (right to buy)
A - Award 100,000 100,000
2017-03-17 2017-03-15 4 TXMD TherapeuticsMD, Inc.
Non-qualified stock option (right to buy)
A - Award 40,000 40,000
2015-12-21 2015-12-17 4 TXMD TherapeuticsMD, Inc.
Non-Qualified Stock Option (right to buy)
A - Award 100,000 100,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)